THE B-CELL RESPONSE TO PRIMARY AND BOOSTER DOSES OF MENACWY‑CRM VACCINE ADMINISTERED AT 2, 4 AND 12 MONTHS OF AGE
ESPID Education. Blanchard-Rohner G. Jun 7, 2011; 7769
Dr. Geraldine Blanchard-Rohner
Dr. Geraldine Blanchard-Rohner

This content is available to ESPID members only


Click here for more information or if you are considering becoming an ESPID member.

Abstract
Discussion Forum (0)
Rate & Comment (0)
The B-cell response to primary and booster doses of an investigational
MenACWY-CRMvaccine administered at 2, 4 and 12 months of age
Geraldine Blanchard-Rohner
1,2
, Matthew D. Snape
1
, Dominic F. Kelly
1
, Tessa
John
1
, Daniel O’Connor
1
, Elizabeth A. Clutterbuck
1
,Brigitte Ohene-Kena
1
, Chaam
Klinger
1
, Hannah Parks
1
, Elizabeth Kibwana
1
, Seema Brar
1
, Peter Dull
3
, Piotr
Juszczak
3
, and Andrew J. Pollard
1
1
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
2
University Hospital of Geneva, Geneva, Switzerland
3
Novartis Vaccines and Diagnostics, Cambridge, MA and Siena, Italy
Background and aims: A new quadrivalent meningococcal vaccine conjugated to CRM
(MenACWY-CRM) is immunogenic in young infants. In this study we assessed the
memory B-cell and antibody responses after a primary course and a booster dose of
MenACWY-CRM in infants.
Methods: 216 healthy infants were primed at 2 and 4 months of age and boosted at 12
months of age with MenACWY-CRM. Blood samples were obtained from all children at
5, 12 and 13 months of age. The memory B-cell response was measured by ELISPOT
and serum antibodies measured using a serum bactericidal assay with human complement
(hSBA).
Results: At 5 months of age, after primary immunisation, serogroup-specific memory Bcells
were detectable in fewer than 25% of children, although protective hSBA antibody
titres (≥1:8) were detectable in more than 94% of children against serogroup C and W-
135, in 87% against serogroups Y, and in 58% against serogroup A. At 12 months of age,
before booster immunisation the percentages with hSBA ≥1:8 were 2% for serogroup A,
40% for serogroup C, 59% for serogroup W-135 and 54% for serogroup Y. One month
after the booster dose of MenACWY-CRM over 50% of children had detectable memory
B-cells, more than 98% had protective antibody titres against serogroups C, W-135 and
Y, and 91% against serogroup A.
Conclusions: These data indicate that few antigen-specific anticapsular memory B-cells
can be detected after two doses priming with MenACWY-CRM, however, these cells
rapidly proliferate after booster immunisation and induce a strong bactericidal antibody
response.
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings